/ Home
/ SUBMISSION

/ The BJOC
/ Diamond Open Access
/ Journal Statistics
/ Editorial Board
/ Community
/ Call for papers

/ Latest Articles
/ Most accessed
/ Thematic issues
/ Volumes
/ Authors

/ Alerts

/ TWITTER
/ LINKEDIN
/ Mastodon
/ RSS FEED

Empty search

Article Type

Publication Date Range

Search Tips

This search combines search strings from the content search (i.e. "Full Text", "Author", "Title", "Abstract", or "Keywords") with "Article Type" and "Publication Date Range" using the AND operator.

Search Examples

aromatic	the word “aromatic”
aromatic aldehyde	the word “aromatic” OR “aldehyde”
+aromatic +aldehyde	both words “aromatic” AND “aldehyde”
+aromatic -aldehyde	the word “aromatic” but NOT “aldehyde”
“aromatic aldehyde”	the exact phrase “aromatic aldehyde”
benz*	words which begin with “benz”, such as “benzene” or “benzyl”
benz*yl	words that begin with “benz” and end with “yl”, such as “benzyl” or “benzoyl”
benzyl~	words that are close to the word “benzyl”, such as “benzoyl” (i.e., fuzzy search)

Search results

Search for "side-products in PDCs" in Full Text gives 1 result(s) in Beilstein Journal of Organic Chemistry.

On the design principles of peptide–drug conjugates for targeted drug delivery to the malignant tumor site

Eirinaios I. Vrettos,
Gábor Mező and
Andreas G. Tzakos

Beilstein J. Org. Chem. 2018, 14, 930–954, doi:10.3762/bjoc.14.80

, including important PDCs that have progressed to phase III clinical trials. Last, we address possible difficulties that may emerge during the synthesis of PDCs, as also report ways to overcome them. Keywords: bioconjugates; cancer; drug delivery; PDC; peptide; peptide–drug conjugate; side-products in PDCs

PDF

Graphical Abstract

Figure 1: Conventional chemotherapy versus targeted chemotherapy. Black color = Solid malignant tumor; red = ...

Jump to Figure 1

Figure 2: A. General structural architecture of the ideal navigated drug delivery system [31]. B. General structu...

Jump to Figure 2

Figure 3: Binding and penetration mechanism of iRGD. The iRGD peptide is accumulated on the surface of αv int...

Jump to Figure 3

Figure 4: Representative examples of anticancer drugs utilized for the construction of PDCs. The most usual c...

Jump to Figure 4

Figure 5: Illustration of the drug release mechanism from the self-immolative spacer PABC conjugated to a tum...

Jump to Figure 5

Figure 6: Structures of the PDCs named AN-152 and AN-207.

Jump to Figure 6

Figure 7: Structure of the PDC named AN-238.

Jump to Figure 7

Figure 8: Chemical structure and synthetic scheme for the PDC ANG1005. (A) ANG1005 is composed of three molec...

Jump to Figure 8

Figure 9: Structure of oxime linked Dau–GnRH-III conjugate with or without cathepsin B labile spacer and thei...

Jump to Figure 9

Figure 10: Synthesis of the most effective GnRH-III–Dau conjugate with two drug molecules [153].

Jump to Figure 10

Figure 11: Structures of the four different PDCs of D-Lys⁶-GnRH-I and gemcitabine (GSG, GSG₂, 3G, 3G₂) [19].

Jump to Figure 11

Figure 12: Structures of (A) native sunitinib; (B) SAN1 analog of sunitinib and (C) assembled PDC named SAN1GS...

Jump to Figure 12

Figure 13: Synthetic scheme for the formation of GSG and the unexpected side product [156].

Jump to Figure 13

Figure 14: Illustration of uncharted guanidinium peptide coupling reagent side reactions during PDCs synthesis ...

Jump to Figure 14

Figure 15: Putative mechanism for the formation of the uronium side product [156].

Jump to Figure 15

Album

Review

Published 26 Apr 2018

Full text

Other Beilstein-Institut Open Science Activities

/ Help / Support & Contact / Alerts / Privacy Policy / Terms & Conditions / Impressum